Use the hyperlinks, where available to access additional clinical trial information.
A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors
This trial has one experimental arm broken into two parts. In Part 1 (dose escalation), participants will receive WM-S1-030 orally by itself. Once the MTD or recommended dose is identified in Part 1, additional participants will be enrolled into Part 2 (dose expansion) to further investigate efficacy, safety and pharmacodynamics, dosing interval or schedule, and food effect on the single dose PK of WM-S1-030. WM-S1-030 orally administered once daily (QD) for 28 days of each cycle.